At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, the U.S. Health Resources and Services Administration (HRSA) said this week.
…
Month: April 2022
340B disproportionate share (DSH) hospitals’ contract pharmacies and child sites often are in richer and less diverse places where more residents have health insurance compared with the hospitals’ own locations, according to a new study.
Healthcare consulting firm Avalere Health
…
Many National Cancer Institute (NCI) designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially,” according to new research in JAMA Internal Medicine. Hospital groups have pointed
…
SPONSORED CONTENT
With so many competing priorities dominating each workday, it can feel overwhelming to keep track of the latest developments that affect the 340B Program. For 340B stakeholders responsible for maintaining compliance, operating a strong program, and maximizing their resources in this complex and ever-changing landscape, keeping up with policies and operational best practices is mission-critical. There is a one-stop solution that 340B experts have used since 2019: the annual 340B Trends & Hot Topics module from the Apexus Advanced 340B Operations Certificate Program. Apexus experts keep the module current with the latest 340B news, legislative activity, and operational challenges and solutions affecting all 340B stakeholders.
In the new 340B Trends & Hot Topics module, 340B stakeholders can explore various 340B expert perspectives regarding strategies for implementing a compliant 340B program in their respective entities.
The newest 340B Trends & Hot Topics module covers a range of 340B hot topics, including the
…
A nationally prominent drug policy expert and two colleagues at Harvard Medical School have written in JAMA how Congress could end the fight over 340B contract pharmacy and enhance 340B program integrity.
“First, Congress could explicitly allow the participation of
…
A federal district judge in Indianapolis last week responded to a higher court’s directive and entered an amended partial final judgement in drug manufacturer Lilly’s 340B contract pharmacy lawsuit. It is not clear whether the judge did enough to satisfy
…
SPONSORED CONTENT
The AIDS Healthcare Foundation thrift store division, Out of the Closet, presents a fun, stigma-free opportunity to link people to care. Every Out of the Closet thrift store benefits AHF’s life-saving programs around the world because 96 cents of every dollar spent at an OTC goes back to HIV care and services. Those services include HIV and STI testing, treatment, and securing medications for AHF Pharmacy clients.
OTC aims to serve a person’s life, not just a diagnosis. With Out of the Closet’s all-in-one model, people can donate old belongings, thrift for new clothes and furniture at an affordable price, grab free condoms to practice safer sex, receive HIV testing, get a referral for treatment if a reactive result occurs, and get linked to care in fewer than 72 hours.
No other shopping experience allows people to provide for their livelihood and receive care all under one roof. In most OTCs,
…
Drug manufacturer Sanofi has made two major changes to its conditions on 340B pricing when health centers and certain hospitals and use contract pharmacies, a company spokesperson confirms. One is raising flags among 340B providers and the other appears to
…
Bristol Myers Squibb has disclosed its terms of use for the drug claims data that providers must give it in exchange for access to 340B pricing on BMS’s oral oncology drugs Revlimid, Pomalyst, and Thalomid.
BMS acquired the three drugs
…
SPONSORED CONTENT
With more and more drug manufacturers excluding their products from 340B contract pharmacies, covered entities are asking two questions: When does this end? And what should we do about it? At Sentry, we’re asking ourselves, how can we best support our customers in these challenging circumstances?
With drugs like AbbVie’s best-selling Humira, Merck’s Keytruda and diabetic drugs from five different manufacturers, it’s safe to say that the contract pharmacy exclusions are taking an ever-increasing bite out of covered entities’ 340B benefits and curtailing their ability to provide critical safety-net services in their communities. We know this from speaking with thousands of covered entity end-users, stakeholders, and advocates. One customer of ours, a large urban health system, has lost over $70 million in program benefits to date from Sanofi alone. The impact is real and has lasting effects on caring for the most vulnerable.
During our February webinar where we discussed the “Manufacturer Mayhem,” I did
…